Skip to search boxSkip to navigationSkip to main content

The management of oral human papillomavirus with topical cidofovir: A case report

  • Scott S. DeRossi(corresponding author)
    ,
  • Joel Laudenbach
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Cidofovir, a purine nucleotide analog of cytosine, has showed significant promise against a number of DNA viruses. In 1997, the US Food and Drug Administration approved the use of cidofovir intravenously in the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Recent studies and reports suggest that a topical form of cidofovir may be useful for treating viral cutaneous lesions recalcitrant to traditional treatments. We report the case of a 36-year-old man with human immunodeficiency virus (HIV) and recalcitrant human papillomavirus (HPV) lesions on the gingiva that were successfully treated with cidofovir gel 1%.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 191-193 (3 pages)

Journal (Volume, Issue Number)

Cutis (Volume 73, Issue 3)

Publication milestones

  • Published - 03/01/2004

Publication status

Published - 03/01/2004

ISSN

0011-4162

Publication IDs

  • Scopus: 1842506709
  • PubMed: 15074348

Publication metrics

Metrics

SciVal
citations
9
SciVal
FWCI
0.61
SciVal
Author count
2
SciVal
Paper percentile
56
Scopus
citations
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1

PlumX

Citation count
13
Captures
17